PharmTech Drug Digest 11.20
News|Articles|July 11, 2016

Patheon Announces Initial Public Offering

Patheon launches initial public offering to repay outstanding notes and expenses.

Patheon announced on July 11, 2016, the commencement of the initial public offering of 30,487,805 of its ordinary shares for an expected price between $19.00 and $22.00 per share.

According to a statement, the company intends to use the proceeds of the sale and cash on hand to repay its outstanding $550 million of Senior PIK Toggle Notes, and pay related fees, expenses, and accrued interest.

The company is selling 25,609,756 ordinary shares and a selling stockholder is selling 4,878,049 ordinary shares. Patheon will not receive any proceeds from the sale of ordinary shares by the selling stockholder.

The ordinary shares of the company will be listed on the New York Stock Exchange under the symbol "PTHN".

In June 2015, Patheon filed a registration statement with the Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. 

Source: Patheon

 

 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.